arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Longeveron Inc.

LGVN
$0.77 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
30 Metrics
Absolute Benchmarks
Price Chart
38
Health
Weak
Bearish Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, Longeveron Inc. shows weak fundamentals, weighed down by Return on Invested Capital and FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $19.1B
Dividend Yield
Revenue Growth 4.5%
Op. Margin None
ROIC -23.5%
FCF / Share $-0.00
Trailing P/E
Price / Book 1190.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$398.00K
↑ +4.5%
Net Income Profit after all expenses
$-4.74M
↑ +5.5%
Operating Margin Operating profit as % of sales
-117.2%
↓ -128.2%
FCF / Share Free cash flow per share
$-0.00
↑ +44.2%
Long-Term Debt Long-term obligations
$143.00K
↓ -1.4%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Invested CapitalReturn on Invested Capital of -324.2% is weak on an absolute basis (target > 10%)
  • FCF / Net IncomeFCF / Net Income of 0.83x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
38

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters